Checkpoint Names James Oliviero President & CEO

Checkpoint Therapeutics Inc., a Fortress Biotech Company, has named James Oliviero as president and chief executive officer. Mr. Oliviero will also be appointed to Checkpoint’s board. Michael Weiss, will remain as executive chairman.

“We are very excited to have James join Checkpoint. James is a seasoned biotech executive with strong operational and financial expertise. James’ experience ranges from capital raising and managing relationships with Wall Street to playing an instrumental role in the approval of Auryxia, a drug we licensed and developed together at Keryx. Those skills will prove invaluable as we drive to build and grow Checkpoint into a major immuno-oncology company,” said Mr. Weiss.

Mr. Oliviero has over fifteen years of operational experience in the biotechnology industry. From May 2003 to September 2015, he served in a variety of leadership capacities at Keryx Biopharmaceuticals, most recently as its chief financial officer since April 2009, where he was instrumental in the growth of the company to a market capitalization over $1 billion.